Copyright © Inderes 2011 - present. All rights reserved.

Aiforia Technologies

1.99 EUR

+9.34 %

2,153 following
Corporate customer

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

+9.34 %
-11.95 %
-20.08 %
-18.11 %
-31.85 %
-47.07 %
-52.62 %
-
-60.67 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
67.05M EUR
Turnover
245.01K EUR
P/E (adj.) (25e)
-5.15
EV/EBIT (adj.) (25e)
-5.85
P/B (25e)
5.09
EV/S (25e)
19.21
Dividend yield-% (25e)
-
Coverage
Recommendation
Accumulate
Target price
3.20 EUR
Updated
19.11.2025
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 19.11.2025

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
2.4
2026

General meeting '26

28.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
The numbers have been tallied, and this is what it looks like. No separate guidance for 2026 is being provided. Compared to Inderes’ expectations, the top line is slightly over in monetary terms (220 kEUR), and more clearly in percentage terms. The bottom lines, on the other hand...
22 hours ago
by Opa
29
Here is a recent interview. Inderes Aiforia H2’25: Kasvua ja kaupallisia edistysaskeleita - Inderes Aika: 06.03.2026 klo 12.36 Aiforian H2-liikevaihto kasvoi vertailukaudesta 45 % ja ylitti ennusteemme selvästi. Kulusäästöt näkyivät käyttökatteessa, mutta kassan palamisvauhti on ...
18 hours ago
by Thiebault
22
At first glance, great stuff! Revenue growth from clinical accounts has finally gained traction. As I understand it, the slow materialization of clinical revenue has been the factor that has unnerved investors over the last few half-year periods. In my opinion, the story has now ...
21 hours ago
by JusaVaan
19
A great half-year in my opinion. We finally got that long-awaited growth, even exceeding forecasts. The cost side will surely get sorted out in time, given the clinical side has such good margins. If it is possible for @Antti_Siltanen to ask Jukka questions, would it be possible ...
22 hours ago
by Jekkku
16
Here are Siltanen’s preview comments as Aiforia reports its H2 results on Friday, March 6. We expect Aiforia’s revenue growth to have accelerated towards the end of the year, supported by the ramp-up of clinical customer accounts. We estimate the result to have remained loss-making...
3/4/2026, 5:15 AM
by Sijoittaja-alokas
13
It looks like we’ll have time to get the H1/26 report out before the next offering is needed, so if growth in clinical use continues well (and why wouldn’t it), the share price probably won’t be this low, considering the potential offering. Will there be an Inderes interview with...
18 hours ago
by Puutaheinää
10
Unfortunately, the questions went unnoticed in the rush between the report and the webcast/interview. The intention is, of course, to always include questions. This is an angle that is raised quite often. Usually, companies’ response is something along the lines of: a directed issue...
16 hours ago
by Antti Siltanen
9
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.